header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-MRPHLNO-050722-6
Morpholino Name: MO2-ptgs2a
Target: ptgs2a (1)
Previous Names: MO2-ptgs2, zCOX-2-B (1)

Add new Alias

Alias
Attribution

Attributions for Alias: {{control.newAlias}}

{{pub.zdbID}}

Delete Alias:

(Including Attributions)
Sequence:
5' - GCTGTTGAAGCAGAGATGCGTTACT - 3'
   
Select Sequence Analysis Tool

  (Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.)
Note: designed against 5'-UTR
TARGET LOCATION
No data available
CONSTRUCTS WITH SEQUENCES FROM MO2-ptgs2a No data available
GENE EXPRESSION
Gene expression in Wild Types + MO2-ptgs2a No data available
PHENOTYPE
Phenotype resulting from MO2-ptgs2a
Phenotype of all Fish created by or utilizing MO2-ptgs2a
Phenotype Fish Conditions Figures
exocrine pancreas prss1 expression amount, ameliorated WT + MO1-ptgs2a + MO2-ptgs2a chemical treatment: prostaglandin E2 Fig. 2 with image from Nissim et al., 2014
exocrine pancreas prss1 expression decreased distribution, abnormal WT + MO1-ptgs2a + MO2-ptgs2a control Fig. 2 with image from Nissim et al., 2014
exocrine pancreas size, ameliorated WT + MO1-ptgs2a + MO2-ptgs2a chemical treatment: prostaglandin E2 Fig. 2 with image from Nissim et al., 2014
exocrine pancreas decreased size, abnormal WT + MO1-ptgs2a + MO2-ptgs2a control Fig. 2 with image from Nissim et al., 2014
hematopoietic stem cell decreased amount, abnormal WT + MO1-ptgs2a + MO2-ptgs2a standard conditions Fig. S1 from North et al., 2007
cilium assembly decreased process quality, abnormal WT + MO2-ptgs2a standard conditions Fig. 5 from Jin et al., 2014
brain ventricular system edematous, abnormal WT + MO2-ptgs2a standard conditions Fig. 5 from Jin et al., 2014
lateral crista has fewer parts of type lateral crista kinocilium, abnormal WT + MO2-ptgs2a standard conditions Fig. 5 from Jin et al., 2014
liver EGFP expression decreased distribution, abnormal as3Tg + MO1-ptgs2a + MO2-ptgs2a control Fig. 1 with image from Nissim et al., 2014
liver size, ameliorated as3Tg + MO1-ptgs2a + MO2-ptgs2a chemical treatment: prostaglandin E2 Fig. 1 with image from Nissim et al., 2014
liver EGFP expression amount, ameliorated as3Tg + MO1-ptgs2a + MO2-ptgs2a chemical treatment: prostaglandin E2 Fig. 1 with image from Nissim et al., 2014
liver decreased size, abnormal as3Tg + MO1-ptgs2a + MO2-ptgs2a control Fig. 1 with image from Nissim et al., 2014
exocrine pancreas size, ameliorated zf578Tg + MO1-ptgs2a + MO2-ptgs2a chemical treatment: prostaglandin E2 Fig. 2 with image from Nissim et al., 2014
exocrine pancreas decreased size, abnormal zf578Tg + MO1-ptgs2a + MO2-ptgs2a control Fig. 2 with image from Nissim et al., 2014
brain ventricular system edematous, abnormal WT + MO1-ptgs1 + MO2-ptgs2a standard conditions Fig. 5 from Jin et al., 2014
OTHER MO2-ptgs2a MORPHOLINO PAGESNo links to external sites
CITATIONS (4)